Fortress Biotech, Inc. (FBIO) vs Gain Therapeutics, Inc. (GANX)

Fortress Biotech, Inc. and Gain Therapeutics, Inc. are both Biotechnology companies. Fortress Biotech, Inc. and Gain Therapeutics, Inc. are of similar size ($80.3M and $76.0M). Gain Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Fortress Biotech, Inc. trades at 0.7×. Gain Therapeutics, Inc. grew revenue faster over the last twelve months: 18.4% against 15.5%. Fortress Biotech, Inc. has the higher net margin (151.0% vs 0.00%) and the lower return on invested capital (−41.3% vs 0.00%). Across the 18 metrics below, Fortress Biotech, Inc. leads on 12 and Gain Therapeutics, Inc. on 6.

Valuation

Metric FBIO GANX Biotechnology median
P/E 0.70 n/m 7.88
P/S 1.06 397.40 11.47
P/B 0.35 6.87 2.52
Price to free cash flow 0.84 n/m 21.16
EV/EBITDA 4.22 n/m 0.74
EV/Sales (1.25) 332.17 10.73
Earnings yield 142.98% (27.62%) (28.84%)
Free cash flow yield 118.43% (24.45%) (23.03%)

Profitability

Metric FBIO GANX Biotechnology median
Gross margin 65.59% 0.00% 65.16%
Operating margin (42.61%) 0.00% 0.00%
Net margin 150.98% 0.00% 0.00%
Free cash flow margin 183.80% 0.00% 0.00%
Return on equity 84.91% (268.30%) (57.72%)
Return on assets 43.38% (159.22%) (49.22%)
Return on invested capital (41.34%) 0.00% 0.00%

Growth

Metric FBIO GANX Biotechnology median
Revenue growth (TTM) 15.46% 18.36% 5.64%
EPS growth (last fiscal year) 97.40% 31.46% —
Revenue growth, 5-year CAGR 6.77% 21.79% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FBIO GANX Biotechnology median
Debt to equity 0.17 0.03 0.00
Current ratio 3.96 4.36 4.73
Net debt to EBITDA 0.43 1.10 0.96

Dividend

Metric FBIO GANX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric FBIO GANX Biotechnology median
Market cap 76.04m 80.30m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack